Paratek Pharmaceuticals Inc (PRTK) Given Consensus Recommendation of “Buy” by Analysts

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has been given an average recommendation of “Buy” by the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $34.29.

PRTK has been the topic of several recent analyst reports. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Guggenheim set a $26.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 3rd. ValuEngine raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Bank of America initiated coverage on shares of Paratek Pharmaceuticals in a research note on Monday, August 27th. They set a “neutral” rating and a $13.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 3rd.

PRTK traded down $0.31 during trading on Wednesday, reaching $9.01. The stock had a trading volume of 680,278 shares, compared to its average volume of 637,220. The company has a market capitalization of $307.78 million, a price-to-earnings ratio of -2.77 and a beta of 0.57. The company has a debt-to-equity ratio of 2.37, a current ratio of 7.88 and a quick ratio of 7.88. Paratek Pharmaceuticals has a 1-year low of $8.69 and a 1-year high of $24.70.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). Paratek Pharmaceuticals had a negative net margin of 1,961.41% and a negative return on equity of 106.39%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Equities analysts expect that Paratek Pharmaceuticals will post -3.41 EPS for the current fiscal year.

In other news, VP Adam Woodrow sold 8,750 shares of the company’s stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total value of $85,925.00. Following the transaction, the vice president now directly owns 112,917 shares of the company’s stock, valued at $1,108,844.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Evan Loh sold 8,861 shares of the company’s stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total transaction of $87,015.02. Following the completion of the transaction, the chief operating officer now directly owns 235,286 shares in the company, valued at $2,310,508.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,503 shares of company stock worth $407,559. Company insiders own 6.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of PRTK. Balter Liquid Alternatives LLC acquired a new position in shares of Paratek Pharmaceuticals in the second quarter worth $137,000. Cubist Systematic Strategies LLC acquired a new position in shares of Paratek Pharmaceuticals in the first quarter worth $147,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Paratek Pharmaceuticals by 81.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 6,625 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of Paratek Pharmaceuticals in the second quarter worth $154,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Paratek Pharmaceuticals in the first quarter worth $162,000. 77.31% of the stock is currently owned by institutional investors and hedge funds.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Read More: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply